** Shares of medical device maker Dexcom DXCM.O fall 6.2% to $73 in extended trade
** Co says it had received a warning letter from the U.S. FDA following inspections of its two key manufacturing facilities
** The warning letter contains observations and identified issues in manufacturing processes and quality management system at DXCM's facilities in San Diego, California and Mesa, Arizona
** Co does not expect a material impact from the letter to its manufacturing capacity or its sales outlook for fiscal year 2025
** DXCM fell 37.3% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。